MacuTherm laser treatment study for intermediate age-related macular degeneration
Part of Eyes & vision clinical trials.
This study tests a new laser treatment (MacuTherm) for intermediate age-related macular degeneration (iAMD), an eye condition that affects central vision. The study aims to see if this treatment can slow or prevent progression to more advanced stages of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 90 years old
- You have intermediate AMD (AREDS category 3) with specific drusen and retinal changes visible on eye exam
- Your best corrected vision is between 20/40 and 20/25 in the study eye
- You have not had cataract surgery in the past 3 months or other eye surgery in the past 6 months
- You are not pregnant or breastfeeding and have no serious medical conditions that would prevent study participation
- You have not received previous thermal laser or radiation treatment to the macula or eye area
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new light-based treatment for intermediate age-related macular degeneration (AMD), a common eye condition that can lead to vision loss. The goal is to see if it is safe and helps slow down the disease.
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
This study tests new ways to measure vision and take detailed eye images in people with age-related macular degeneration (AMD), a common eye condition affecting central vision. The goal is to develop better tools for future AMD treatment trials.
This study tests whether a special low-level laser treatment (photobiomodulation) can help people with an early form of age-related macular degeneration called reticular pseudodrusen. It may slow vision loss or protect your eyes from getting worse.
This trial studies a mild (“subthreshold”) laser treatment for reticular pseudodrusen (RPD) caused by age-related macular degeneration (AMD). If you qualify, the goal is to see whether the laser helps preserve or improve vision by targeting these specific eye changes.
This study tests whether low-level red-light therapy can help people with dry age-related macular degeneration (AMD), a common cause of vision loss in older adults. The therapy is a painless light treatment that you might receive in multiple sessions, and the study aims to see if it can slow or improve vision decline.
Hear when a new Intermediate AMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.